• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Allakos Inc.

    5/27/25 9:00:14 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLK alert in real time by email
    15-12G 1 ef20049661_1512g.htm 15-12G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 15
     
    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
     
    001-38582
    Commission File Number

    ALLAKOS INC.
    (Exact name of registrant as specified in its charter)

    149 Commonwealth Drive, Suite 1090
    Menlo Park, California 94025
    (650) 597-5002
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, $0.001 par value per share
    (Title of each class of securities covered by this Form)

     None
    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
     
     
    Rule 12g-4(a)(1)
    ☒
     
    Rule 12g-4(a)(2)
    ☐
     
    Rule 12h-3(b)(1)(i)
    ☒
     
    Rule 12h-3(b)(1)(ii)
    ☐
     
    Rule 15d-6
    ☐
     
    Rule 15d-22(b)
    ☐

    Approximate number of holders of record as of the certification or notice date:
      One



    Pursuant to the requirements of the Securities Exchange Act of 1934, Allakos Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
     
    Date: May 27, 2025           
    ALLAKOS INC.
       
      By:
    /s/ Michael Hearne
       
    Name: Michael Hearne
       
    Title: Chief Financial Officer



    Get the next $ALLK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLK

    DatePrice TargetRatingAnalyst
    1/17/2024$6.00 → $1.50Buy → Hold
    Jefferies
    1/16/2024Overweight → Neutral
    Cantor Fitzgerald
    12/18/2023Mkt Perform → Outperform
    William Blair
    12/8/2023$9.00 → $6.00Buy
    Jefferies
    9/27/2023$11.00Mkt Outperform
    JMP Securities
    5/12/2023$6.00 → $9.00Hold → Buy
    Jefferies
    3/7/2023$22.00Overweight
    Piper Sandler
    9/12/2022$2.00Neutral → Underperform
    SMBC Nikko
    More analyst ratings

    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bvf Partners L P/Il returned 16,312,872 shares to the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/19/25 6:45:29 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walker Paul Edward returned 6,147,260 shares to the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/15/25 4:28:27 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Tomasi Adam returned 533,420 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/15/25 4:08:04 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

    SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro

    4/2/25 8:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

    SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua

    3/12/25 4:02:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

    2/11/25 11:30:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allakos downgraded by Jefferies with a new price target

    Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously

    1/17/24 7:08:59 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Allakos from Overweight to Neutral

    1/16/24 1:35:19 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos upgraded by William Blair

    William Blair upgraded Allakos from Mkt Perform to Outperform

    12/18/23 6:44:17 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    SEC Filings

    View All

    SEC Form 15-12G filed by Allakos Inc.

    15-12G - Allakos Inc. (0001564824) (Filer)

    5/27/25 9:00:14 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Allakos Inc.

    SCHEDULE 13G/A - Allakos Inc. (0001564824) (Subject)

    5/19/25 6:42:25 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Allakos Inc.

    SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)

    5/19/25 4:15:11 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Leadership Updates

    Live Leadership Updates

    View All

    Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

    2/11/25 11:30:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Appoints Neil Graham to its Board of Directors

    SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph

    8/30/23 4:05:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

    SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well

    8/2/23 4:05:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Financials

    Live finance-specific insights

    View All

    Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

    – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme

    1/27/25 7:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Announces a Restructuring to Focus on Development of AK006

    Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c

    1/16/24 7:02:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

    – Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m

    1/16/24 7:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Allakos Inc.

    SC 13G - Allakos Inc. (0001564824) (Subject)

    11/12/24 9:50:12 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allakos Inc.

    SC 13G/A - Allakos Inc. (0001564824) (Subject)

    7/8/24 4:32:41 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

    SC 13G/A - Allakos Inc. (0001564824) (Subject)

    2/14/24 4:58:16 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care